指南解读

中国支气管哮喘防治指南(2020年版)解读

展开
  • 上海交通大学附属第一人民医院呼吸与危重症医学科,上海 200080

收稿日期: 2021-02-20

  网络出版日期: 2022-06-28

本文引用格式

周新, 张旻 . 中国支气管哮喘防治指南(2020年版)解读[J]. 诊断学理论与实践, 2021 , 20(02) : 138 -143 . DOI: 10.16150/j.1671-2870.2021.02.004

参考文献

[1] 中华医学会呼吸病学分会哮喘学组. 支气管哮喘防治指南(2020年版)[J]. 中华结核和呼吸杂志, 2020, 43(12):1023-1048.
[2] 中华医学会呼吸病学分会哮喘学组. 支气管哮喘防治指南(2016年版)[J]. 中华结核和呼吸杂志, 2016, 39(9):675-697.
[3] Lin J, Wang W, Chen P, et al. Prevalence and risk factors of asthma in mainland China: the CARE study[J]. Respir Med, 2018, 137:48-54.
[4] Huang K, Yang T, Xu J, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study[J]. Lancet, 2019, 394(10196):407-418.
[5] Su N, Lin J, Chen P, et al. Evaluation of asthma control and patient’s perception of asthma: findings and analysis of a nationwide questionnaire-based survey in China[J]. J Asthma, 2013, 50(8):861-870.
[6] 林江涛, 王文巧, 周新, 等. 我国30个省市城区门诊支气管哮喘患者控制水平的调查结果[J]. 中华结核和呼吸杂志, 2017, 40(7):494-498.
[7] 中华医学会变态反应分会呼吸过敏学组(筹), 中华医学会呼吸病学分会哮喘学组. 中国过敏性哮喘诊治指南(第一版,2019年)[J]. 中华内科杂志, 2019, 58(9):636-655.
[8] 中华医学会呼吸病学分会哮喘学组, 中国哮喘联盟. 重症哮喘诊断与处理中国专家共识[J]. 中华结核与呼吸杂志, 2017, 40(11):813-829.
[9] Sheikh A. Diagnosis and management of difficult-to-treat and severe asthma in adolescent and adult patients[R/OL]. [2021-02-20]. http://www.ginasthma.org/local/uploads/2019/04/GINA-Severe-asthma-Pocket-Guide-v2.0-wms-1.
[10] Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review[J]. Chest, 2011, 139(1):28-35.
[11] Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial[J]. Lancet Respir Med, 2017, 5(5):390-400.
[12] Bjermer L, Lemiere C, Maspero J, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study[J]. Chest, 2016, 150(4):789-798.
[13] FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma(CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial[J]. Lancet, 2016, 388(10056):2128-2141.
[14] Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma[J]. N Engl J Med, 2018, 378(26):2486-2496.
[15] Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline[J]. Eur Respir J, 2020, 55(1):1900588.
[16] 农英, 苏楠, 林江涛, 等. 支气管热成形术治疗重度支气管哮喘的有效性和安全性研究[J]. 中华结核与呼吸杂志, 2016, 39(3):177-182.
文章导航

/